MK 3866

Drug Profile

MK 3866

Alternative Names: MK-3866

Latest Information Update: 04 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 24 Apr 2018 Merck terminates a phase I trial in Merck due to further evaluations of ongoing animal safety investigations (NCT03295266)
  • 09 Feb 2018 Merck Sharp & Dohme completes a phase-I clinical trials in Bacterial infections in USA (IV) (NCT03259087)
  • 11 Dec 2017 Merck Sharp & Dohme initiates enrolment in the phase I MK-3866-006 pharmacokinetic trial in Healthy volunteers in USA (IV) (NCT03295266)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top